News and Comments

Aimmune Therapeutics: Oral Peanut desensitization Treatment is Promising

  Wednesday, November 11, 2015

Food allergies are bad, significant, dangerous and growing in the U.S. and the rest of the world. More than 30 million people in the United States and Europe have a food allergy, and more than five million people in the United States and Europe have peanut allergy, including more than two million children.  More...

Exeixis Will Begin Reaping the Fruits

  Tuesday, November 10, 2015


Incyte is A Great Biotech Firm

  Saturday, November 07, 2015

To shareholders who were stupefied with an instigated selloff of Incyte’s (INCY) stock today, we say do not get panicky. Nothing is wrong with Incyte, no bad news was announced with any of the firm’s 12 ongoing clinical trials or with its approved drug Jakafi, which demonstrated progressive growth since it was launched.  So, a clever correct move now would be taking advantage and accumulate INCY.  More...

Dyax Acquisition and Biocryst Future

  Tuesday, November 03, 2015


Another Durable Botulinum Toxin with Many Advantages Over Botox

  Thursday, October 29, 2015

Another Durable, Botulinum Toxin with Many Advantages More...

Cytokinetics Heart Failure Drug Worked

  Tuesday, October 27, 2015



  Thursday, October 22, 2015

The FDA issued a warning that hepatitis C treatment Viekira Pak and Technivie can cause serious side effects and serious liver injury, mostly in patients with underlying advanced liver disease.  More...

The Stream of Exelixis Good News is Real

  Thursday, October 22, 2015


Sarepta Versus Biomarin: Trying to make an Educated Guess

  Monday, October 19, 2015

About Duchenne muscular Dystrophy treatments, bloggers tried to explain the reasons that led the FDA to decide upon reviewing Biomarin’s (BMRN) Duchenne muscular dystrophy (DMD) drug Drisapersen a few weeks earlier than reviewing Sarepta (SRPT) DMD drug Eteplirsen.  More...

Incyte And Merck Agree to Expand Their agreement Regarding their Immunotherapy Combination Drugs

  Tuesday, October 13, 2015


Recent Postings



Vitae Pharmaceuticals (VTAE) SYNTA (SNTA) ISIS (ISIS) BIOMARIN (BMRN) GlaxoSmithKline (GSK) Agenus (AGEN Theravance Bio Pharma (TBPH) Vertex (VRTX) Tysabri Valeant Pharmaceuticals International (VRX) SUNESIS PHARMACEUTICALS (SNSS) Ridaforolimus Sanofi-Aventis (SAN) Alder Biopharmaceuticals (ALDR) Intermune (ITMN) ZALTRAP™ Multiple Myeloma Jazz Pharmaceuticals (JAZZ) HALOZYME (HALO) Galena (GALE) Gilead (GILD) NOVOCURE (NVCR) INNOVIVA (INVA) VANDA (VNDA) Herceptin ADVENTRIX (ANX) Rapamune Abbott Laboratories (ABT) Biogen Idec (BIIB) CompuGen (CGEN) Sangamo (SGMO) Benlysta (belimumab) Telaprevir Pluristem (PSTI) Revlimid (lenolidamide) Illumina (ILMN) KERYX (KERX) Micromet (MITI) Trastuzumab-DM1 Sarepta (SRPT) Dynavax (DVAX) Regeneron (REGN) Genentech KITE (KITE) galapagos (GLPG) ACADIA (ACAD) Elan (ELN) ARCA (ABIO) Roche (ROCHE) NANTKWEST (NK) Sequenom (SQNM) Velcade (bortezomib) Onyx (ONXX) ImmunoGen (IMGN) Seattle Genetics (SGEN) Xoma (XOMA) Exelixis (EXEL) ABBVIE (ABBV) JUNO (JUNO) Spike Therapeutics (ONCE) OSI (OSIP) Intercept (ICPT) Sanofi (SNY) Dendreon (DNDN) Bristol-Myers Squibb (BMY) Global Cell Therapeutics (GBT) Intrexon (XON) RenenxBio (RGNX) Ziofpharm (ZIOP) Human Genome Sciences (HGSI) ARGOS (ARGS) Cytokinetics (CYTK) Anacor (ANAC) Zerenex Prolor Biotech (PBTH) AERIE PHARMACEUTICALS Ionis (IONS) Alnylam (ALNY) NEKTAR (NKTR)) TOKAI (TKAOI) Mirati Therapeutics (MRTX) Biocryst (BCRX) Merck (MRK) Auspex (ASPX) Sanofi (SNA) Array Pharmaceuticals (ARRY) Editas (EDIT) Idenix (IDIX) AGOS (ARGS) C4 Therapeutics Aimmune Therapeutics (AIMT) Human Longevity (HLI) Endometrial Cancer GUARDIAN HEALTH REGULUS (RGLS) Incyte (INCY) Roche (RHHBY) Prosensa (RNA) PTC Therapeutics (PTCT) Inovio (INO) Agenus (AGEN) Theravance (THRX) Anadys (ANDS) Ariad (ARIA) Amgen (AMGN) SERES THERAPEUTICS (MCRB) IDERA (IDRA)